Gansu Shengnuo Pharmaceutical Technology Co., Ltd. was established in April 2019, covering an area of 120 acres with a total construction area of 13,496.2 square meters. The company has a total investment of 130 million yuan, with the first-phase project investing 110 million yuan. It has completed the construction of production lines with an annual output of 1,000 tons of N-methyl-4-nitrophthalimide, 300 tons of 4,4'-oxydiphthalimide, 600 tons of 3-nitrophthalic acid, 300 tons of 4-chlorophthalic anhydride, 1,000 tons of 5-nitroisophthalic acid, 50 tons of 3-nitropyrazole, 200 tons of N-methyl-4-aminophthalimide, 300 tons of 5-aminoisophthalic acid, and 8,000 tons of 3,4-dichloronitrobenzene. Supporting facilities such as storage, tank areas, power distribution, analysis, safety, environmental protection, firefighting, energy conservation, and office and living amenities have also been constructed. The company commenced production in July 2021. A second-phase renovation project with an investment of 20 million yuan was completed, establishing production lines with an annual output of 500 tons of L-theanine and 2,000 tons of dimethyl 5-nitroisophthalate. Trial production acceptance was conducted in August 2024, and current trial production is progressing smoothly with gradually expanding output. The company currently employs 65 staff members, including 11 management personnel and 12 R&D personnel, among whom are 2 PhD holders and 2 bachelor's degree holders. Nine employees have over 10 years of experience in chemical research and development. The company has established departments such as Production, Quality, Safety and Environmental Protection, Finance, Sales, Procurement, Storage, Central Control Room, and General Administration. Production operations include 5 workshops and 8 production lines, one of which is an environmental protection workshop. With strong technical expertise and comprehensive production equipment, the company maintains close collaborations with research institutions such as Nanjing University, China Pharmaceutical University, and Nanjing Tech University. Its independently developed and innovative production processes are stable and reliable, with many products achieving leading domestic quality levels and purities exceeding 99%. The company's products are sold to major renowned pharmaceutical enterprises across the country, with quality surpassing that of similar products in the industry. The company is committed to serving its customers with high-quality products, adhering to the corporate philosophy of "establishing credibility, innovating for long-term development, and prioritizing quality." It persists on the path of "technological collaboration," focusing on high standards, new technologies, and high-quality development.